Tue, Jul 22, 2014, 4:18 AM EDT - U.S. Markets open in 5 hrs 12 mins

Recent

% | $
Click the to save as a favorite.

Isis Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • jetmanbash jetmanbash Jan 4, 2013 5:59 AM Flag

    These law suits are tag along, improperly studied strike complaints

    All excellent points. Everytime we have a lawsuit like this America grows a little bit weaker. If ISIS comes out of this clean all of these law firms should have to reimburse all shareholders not suing who endured a loss in share price because of their thoughtless actions. t

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ISIS never promised it would obtain a license, it disclaimed that it might not get a license in its safe harbor recitals. Two deaths by heart attack and one by liver failure was and is to be expected in the group sizing and 1 + year study period and the specific type of patient. Note that they all were very likely on drug therapies for 20 years prior to entering into the ISIS study. During this trial, many more should have died, so the therapies look to be very, very effective. The cancer risk does not play...ISIS could not sign all of its partnership agreements, not see the trend in its other trials, if there was any trend there. ISIS partners had all these data, they are co principles in the trials!!!. By using a statistic that is near "0", these firms make it look like they will sue no matter what, as soon as one jurisdiction refuses a license. That is simply obvious as to their true intent. Maybe a class action by the current shareholders is in order. It would certainly be novel. Ask that ever short that covered at our expense be disgorged.

      Sentiment: Strong Buy

 
ISIS
28.65-0.09(-0.31%)Jul 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.